Brainstorm Cell Therapeutics Inc.
General ticker "BCLI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.3M (TTM average)
Brainstorm Cell Therapeutics Inc. does not follow the US Stock Market performance with the rate: -20.4%.
Estimated limits based on current volatility of 2.6%: low 0.60$, high 0.63$
Factors to consider:
- Total employees count: 43 as of 2022
- Top business risk factors: Regulatory and compliance, Pandemic risks, Insufficient funding, Market acceptance, Market competition
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.70$, 3.33$]
- 2024-12-30 to 2025-12-30 estimated range: [0.42$, 1.80$]
Financial Metrics affecting the BCLI estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -155.56 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -115.45 <= 18.93
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 16.68 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term BCLI quotes
Long-term BCLI plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $24.54MM | $24.82MM | $21.44MM |
| Operating Income | $-24.54MM | $-24.82MM | $-21.44MM |
| Non-Operating Income | $0.08MM | $0.55MM | $4.25MM |
| R&D Expense | $15.23MM | $13.96MM | $10.75MM |
| Income(Loss) | $-24.46MM | $-24.28MM | $-17.19MM |
| Profit(Loss)* | $-24.46MM | $-24.28MM | $-17.19MM |
| Stockholders Equity | $19.34MM | $-3.02MM | $-4.86MM |
| Assets | $29.28MM | $8.45MM | $4.21MM |
| Operating Cash Flow | $-26.27MM | $-19.32MM | $-20.46MM |
| Capital expenditure | $0.33MM | $0.03MM | $0.02MM |
| Investing Cash Flow | $0.32MM | $1.00MM | $2.19MM |
| Financing Cash Flow | $6.97MM | $0.24MM | $18.98MM |
| Earnings Per Share** | $-10.09 | $-9.93 | $-4.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.